Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues

School of Pharmacy, College Lane Campus, University of Hertfordshire, Hatfield, Herftordshire, AL10 9AB, UK.
Psychopharmacology (Impact Factor: 3.88). 11/2010; 214(3):593-602. DOI: 10.1007/s00213-010-2070-x
Source: PubMed


Recently, those substances deriving from the active ingredient of the Khat plant, cathinone, have been rising in popularity. Indeed, 4-methylmethcathinone (mephedrone; 'meow meow' and others) has been seen by some as a cheaper alternative to other classified recreational drugs.
We aimed here at providing a state-of-the-art review on mephedrone history and prevalence of misuse, chemistry, pharmacology, legal status, product market appearance, clinical/management and related fatalities.
Because of the limited evidence, some of the information here presented has been obtained from user reports/drug user-orientated web sites. The most common routes for mephedrone recreational use include insufflation and oral ingestion. It elicits stimulant and empathogenic effects similar to amphetamine, methylamphetamine, cocaine and MDMA. Due to its sympathomimetic actions, mephedrone may be associated with a number of both physical and psychopathological side effects. Recent preliminary analysis of recent UK data carried out in 48 related cases have provided positive results for the presence of mephedrone at postmortem.
Within the UK, diffusion of mephedrone may have been associated with an unprecedented combination of a particularly aggressive online marketing policy and a decreasing availability/purity of both ecstasy and cocaine. Mephedrone has been recently classified in both the UK and in a number of other countries as a measure to control its availability. Following this, a few other research psychoactives have recently entered the online market as yet unregulated substances that may substitute for mephedrone. Only international collaborative efforts may be able to tackle the phenomenon of the regular offer of novel psychoactive drugs.

Download full-text


Available from: Zsolt Demetrovics,
  • Source
    • "However, after regulatory measures that restrict possession, sale, and manufacture of synthetic cathinones passed in the UK, the number of users who purchased the drug from dealers increased considerably, while its price increased, almost two times higher than its price before legislation [4]. Sometimes mephedrone is sold as either cocaine or ecstasy while cut-agents such as paracetamol, caffeine, amphetamine, ketamine and even cocaine may be found in mephedrone [1] [7]. As reported by users and drug-orientated websites, mephedrone is commonly used recreationally either via oral ingestion or insufflation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this work is to test the stability of mephedrone added to whole blood collected from alive and dead mephedrone free-users and stored at three different temperatures (-20, +4 and +20°C) with and without preservatives up to 6 months, trying to establish the best storage condition in order to reduce possible analyte loss/degradation during the storage period. Different sources of blood were obtained as follow: 10 samples of blood came from 10 alive mephedrone free-users (mean age 34±15.8 years old) (Group 1), whereas 10 post mortem blood samples were obtained from 10 cadavers, in which the post mortem interval was between 24 and 36h (Group 2). The cause of death in post mortem cases (mean age 45±14.2 years old) was not drug related. Pools of blood were spiked with mephedrone at the concentration of 1mg/L and 1mL aliquots were transferred in 2mL Eppendorf capped tubes with and without preservatives as follow: with ethylenediaminetetraacetic acid (EDTA) 3%; with sodium fluoride/potassium oxalate (NaF/KOx) 1.67%/0.2%, respectively; without preservatives. All samples were stored at three different temperatures: -20°C, 4°C and 20°C and extracted and analyzed in duplicate by GC-MS according to a previously published method by Dickson et al., every other day during the first month and then weekly up to 6 months. our study allow us to affirm that -20°C is the best storage temperature for mephedrone stability in ante-mortem and post-mortem blood samples in comparison to the other two tested temperatures (+4 and +20°C), showing higher values in both groups in samples stored with and without preservatives (p<0.0001). The comparison of Group 1 (samples coming from alive subjects) and Group 2 (post-mortem samples) highlights a better stability of mephedrone in Group 1 (p<0.001) at all tested storage conditions. Finally, the analysis of blood specimens stored with and without preservatives in both groups suggests that specimens stored with NaF/KOx maintain mephedrone stability better than those stored with EDTA (p<0.001) and those stored without preservatives (p<0.0001), therefore, we strongly recommend in order to maintain the highest mephedrone stability in blood, to store specimens at -20°C adding NaF/KOx as preservative. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Forensic science international 07/2015; 256:28-37. DOI:10.1016/j.forsciint.2015.07.021 · 2.14 Impact Factor
    • "administration to freely moving rats elevates extracellular levels of dopamine, and to a greater extent 5-HT, in the nucleus accumbens (Kehr et al. 2011; Baumann et al. 2012; Wright et al. 2012). Multiple re-dosing is common with mephedrone users attempting to maintain the desired effects of this shortacting drug, and while a typical recreational dose is often between 100–200 mg, individuals may re-dose and ingest up to 4 g in a single session (Schifano et al. 2011; Winstock et al. 2011). Most studies show the acute effect of a single injection, or self-administration of mephedrone in the rat is hypothermia (Aarde et al. 2013; Miller et al. 2013; Shortall et al. 2013a), but hyperthermia has also been reported following rapid repeated dosing (Hadlock et al. 2011; Baumann et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The psychoactive effects of mephedrone are commonly compared with those of 3,4-methylenedioxymethamphetamine, but because of a shorter duration of action, users often employ repeated administration to maintain its psychoactive effects. This study examined the effects of repeated mephedrone administration on locomotor activity, body temperature and striatal dopamine and 5-hydroxytryptamine (5-HT) levels and the role of dopaminergic and serotonergic neurons in these responses. Adult male Lister hooded rats received three injections of vehicle (1 ml/kg, i.p.) or mephedrone HCl (10 mg/kg) at 2 h intervals for radiotelemetry (temperature and activity) or microdialysis (dopamine and 5-HT) measurements. Intracerebroventricular pre-treatment (21 to 28 days earlier) with 5,7-dihydroxytryptamine (150 µg) or 6-hydroxydopamine (300 µg) was used to examine the impact of 5-HT or dopamine depletion on mephedrone-induced changes in temperature and activity. A final study examined the influence of i.p. pre-treatment (-30 min) with the 5-HT1A receptor antagonist WAY-100635 (0.5 mg/kg), 5-HT1B receptor antagonist GR 127935 (3 mg/kg) or the 5-HT7 receptor antagonist SB-258719 (10 mg/kg) on mephedrone-induced changes in locomotor activity and rectal temperature. Mephedrone caused rapid-onset hyperactivity, hypothermia (attenuated on repeat dosing) and increased striatal dopamine and 5-HT release following each injection. Mephedrone-induced hyperactivity was attenuated by 5-HT depletion and 5-HT1B receptor antagonism, whereas the hypothermia was completely abolished by 5-HT depletion and lessened by 5-HT1A receptor antagonism. These findings suggest that stimulation of central 5-HT release and/or inhibition of 5-HT reuptake play a pivotal role in both the hyperlocomotor and hypothermic effects of mephedrone, which are mediated in part via 5-HT1B and 5-HT1A receptors. © 2015 Society for the Study of Addiction.
    Addiction Biology 07/2015; DOI:10.1111/adb.12283 · 5.36 Impact Factor
  • Source
    • "Source: da-antagonist-market/ Bingham, 2013b) and are untested compounds for which no formal toxicology profiles exist (Schifano et al. 2011; Winstock et al. 2011; Corazza et al. 2012), with scant safety information surrounding content, possible side-effects, and interactions with other substances (Schmidt et al. 2011; Walsh 2011; Kjellgren & Jonsson 2013). Quantitative and qualitative variation in product content, along with misrepresentation of actual contents, occurs (Davies et al. 2010; Schmidt et al. 2011; Zuba & Byrska 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Methoxphenidine (MXP) was one of several NMDA antagonists marketed in 2013 to replace the recently controlled compound Methoxetamine (MXE). A steep rise in user interest was recorded, despite vendor cautioning of limited user feedback. The study presented a phenomenological analysis of MXP experiences amongst recreational drug users as posted on public Internet fora. Internet searches were carried out using specific key words; "methoxphenidine," "MXP" and in combination with "experience," "report," "forum," and "trip." Seven self-reported experiences and 28 thread discussions relating sole use of MXP were analyzed using the Empirical Phenomenological Psychological method. Five themes and 61 categories emerged. MXP is marketed as a legal replacement for MXE, diphenidine, and ketamine, with a dissociative and stimulant wave outcome often lasting for days. Harm reduction tactics, awareness of prior tolerance to dissociative and optimal settings for use are discussed. Acute side-effects relate to hypertension and seizures. Chronic long-term memory loss and limb numbness is reported. Sense of empowerment occurs in the afterglow experience. Internet drug fora fuel information exchange and informed consumerism of synthetic compounds, and offer viable mechanisms for pre- and post-purchase decision making and indigenous harm reduction. Continued surveillance of synthetic market entries and user trends is warranted.
    Journal of psychoactive drugs 02/2015; 47(1):30-41. DOI:10.1080/02791072.2014.974002 · 1.10 Impact Factor
Show more